Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to $17000.0.

  • Relay Therapeutics' Cash from Financing Activities fell 9999.22% to $17000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $221.2 million, marking a year-over-year decrease of 2404.05%. This contributed to the annual value of $270.2 million for FY2024, which is 67735.16% up from last year.
  • Latest data reveals that Relay Therapeutics reported Cash from Financing Activities of $17000.0 as of Q3 2025, which was down 9999.22% from $800000.0 recorded in Q4 2024.
  • In the past 5 years, Relay Therapeutics' Cash from Financing Activities registered a high of $384.0 million during Q4 2021, and its lowest value of $17000.0 during Q3 2025.
  • Moreover, its 5-year median value for Cash from Financing Activities was $2.0 million (2022), whereas its average is $57.8 million.
  • In the last 5 years, Relay Therapeutics' Cash from Financing Activities skyrocketed by 68563571.43% in 2021 and then tumbled by 9999.22% in 2025.
  • Quarter analysis of 5 years shows Relay Therapeutics' Cash from Financing Activities stood at $384.0 million in 2021, then crashed by 99.7% to $1.2 million in 2022, then surged by 1779.76% to $21.9 million in 2023, then tumbled by 96.35% to $800000.0 in 2024, then tumbled by 97.88% to $17000.0 in 2025.
  • Its last three reported values are $17000.0 in Q3 2025, $800000.0 for Q4 2024, and $218.9 million during Q3 2024.